Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 13
Submit an article Journal homepage
431
Views
66
CrossRef citations to date
0
Altmetric
Reviews

Autism: an emerging ‘neuroimmune disorder’ in search of therapy

Theoharis C Theoharides Director, Molecular Immunopharmacology and Drug Discovery Laboratory, Tufts University School of Medicine, Tufts Medical Center, Department of Pharmacology and Experimental Therapeutics, and Departments of Biochemistry, Internal Medicine, and Psychiatry, Molecular Immunopharmacology and Drug Discovery Laboratory, 136 Harrison Avenue, Boston, MA 02111, USA +1 617 636 6866; +1 617 636 2456; [email protected]
, MS MPhil PhD MD FAAAI,
Duraisamy Kempuraj Tufts University School of Medicine, Department of Pharmacology and Experimental Therapeutics, 136 Harrison Avenue, Boston, MA 02111, USA
, MS MPhil PhD &
Lyn Redwood Coalition for Safe Minds and the National Autism Association, 16033 Bolsa Chica St, #104 142, Huntington Beach, CA 92649, USA
, RN MSN
Pages 2127-2143 | Published online: 29 Jul 2009

Bibliography

  • Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006;118(1):e139-50
  • Gerberding J. Prevalence of autism spectrum disorder–Autism and developmental disabilities monitoring network, six sites, United States, 2000 and 2002. MMWR Morb Mortal Wkly Rep 2007;56(1S):1-40
  • Newschaffer CJ, Croen LA, Daniels J, et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health 2007;28:235-58
  • Yeargin-Allsopp M, Rice C, Karapurkar T, et al. Prevalence of autism in a US metropolitan area. JAMA 2003;289(1):49-55
  • Gurney JG, McPheeters ML, Davis MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Arch Pediatr Adolesc Med 2006;160(8):825-30
  • Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007;120(5):1183-215
  • Center for disease control: prevalence of autism spectrum disorders -autism and developmental disabilities monitoring network, six sites, 2000. Morb Mortal Wkly Rep 2007;15:1-11
  • Kuehn BM. CDC: autism spectrum disorders common. JAMA 2007;297(9):940
  • Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009;65(6):591-8
  • Hertz-Picciotto I, Delwiche L. The rise in autism and the role of age at diagnosis. Epidemiology 2009;20(1):84-90
  • Stehr-Green P, Tull P, Stellfeld M, et al. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med 2003;25(2):101-6
  • D'Souza Y, Fombonne E, Ward BJ. No evidence of persisting measles virus in peripheral blood mononuclear cells from children with autism spectrum disorder. Pediatrics 2006;118(4):1664-75
  • Destefano F. Vaccines and autism: evidence does not support a causal association. Clin Pharmacol Ther 2007;82(6):756-9
  • Baker JP. Mercury, vaccines, and autism: one controversy, three histories. Am J Public Health 2008;98:244-53
  • Fombonne E. Thimerosal disappears but autism remains. Arch Gen Psychiatry 2008;65(1):15-6
  • Gallagher C, Goodman M. Hepatitis B triple series vaccine and developmental disability in US children aged 1-9 years. Toxicol Environ Chem 2008;90(5):997-1008
  • Geier DA, Geier MR. A meta-analysis epidemiological assessment of neurodevelopmental disorders following vaccines administered from 1994 through 2000 in the United States. Neuro Endocrinol Lett 2006;27(4):401-13
  • Woo EJ, Ball R, Landa R, et al. Developmental regression and autism reported to the Vaccine Adverse Event Reporting System. Autism 2007;11(4):301-10
  • Young HA, Geier DA, Geier MR. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. J Neurol Sci 2008;271(1-2):110-8
  • Rapin I, Tuchman RF. What is new in autism? Curr Opin Neurol 2008;21(2):143-9
  • Caronna EB, Milunsky JM, Tager-Flusberg H. Autism spectrum disorders: clinical and research frontiers. Arch Dis Child 2008;93(6):518-23
  • Lintas C, Persico AM. Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist. J Med Genet 2009;46:1-8
  • Palmieri L, Papaleo V, Porcelli V, et al. Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1. Mol Psychiatry 2008. [Epub ahead of print]
  • Garbett K, Ebert PJ, Mitchell A, et al. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis 2008;30(3):303-11
  • Lintas C, Sacco R, Garbett K, et al. Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression. Mol Psychiatry 2008;14(7):705-18
  • Persico AM, Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci 2006;29(7):349-58
  • Cai G, Edelmann L, Goldsmith JE, et al. Multiplex ligation-dependent probe amplification for genetic screening in autism spectrum disorders: efficient identification of known microduplications and identification of a novel microduplication in ASMT. BMC Med Genomics 2008;1:50
  • Wang K, Zhang H, Ma D, et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature 2009;459:528-33
  • Glessner JT, Wang K, Cai G, et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 2009;459:569-73
  • Strom SP, Stone JL, Ten B, et al. High-density SNP association study of the 17q21 chromosomal region linked to autism identifies CACNA1G as a novel candidate gene. Mol Psychiatry 2009. [Epub ahead of print]
  • James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006;141(8):947-56
  • James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004;80(6):1611-7
  • Carvalho CM, Chew EH, Hashemy SI, et al. Inhibition of the human thioredoxin system. A molecular mechanism of mercury toxicity. J Biol Chem 2008;283(18):11913-23
  • James SJ, Rose S, Melnyk S, et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB 2009. [Epub ahead of print]
  • Geier DA, Kern JK, Garver CR, et al. A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem Res 2009;34(2):386-93
  • Geier DA, Kern JK, Garver CR, et al. Biomarkers of environmental toxicity and susceptibility in autism. J Neurol Sci 2008;280(1-2):101-8
  • Sajdel-Sulkowska EM, Lipinski B, Windom H, et al. Oxidative stress in autism: elevated cerebellar 3-nitrotyrosine levels. AM J Biochem Biotechnol 2008;4:73-84
  • Yorbik O, Sayal A, Akay C, et al. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids 2002;67(5):341-3
  • James JS, Melnyk S, Jernigan S, et al. Abnormal transmethylation/transsulfuration metabolism and DNA hypomethylation among parents of children with autism. J Autism Dev Disord 2008;38(10):1966-75
  • Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin–the antioxidant proteins. Life Sci 2004;75(21):2539-49
  • Yao Y, Walsh WJ, McGinnis WR, Pratico D. Altered vascular phenotype in autism: correlation with oxidative stress. Arch Neurol 2006;63(8):1161-4
  • Weissman JR, Kelley RI, Bauman ML, et al. Mitochondrial disease in autism spectrum disorder patients: A cohort analysis. PloS One 2008;3(11):e3815
  • Deth R, Muratore C, Benzecry J, et al. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology 2008;29(1):190-201
  • Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry 2005;17(6):485-95
  • Ashwood P, van de Water J. Is autism an autoimmune disease? Autoimmun Rev 2004;3(7-8):557-62
  • Ashwood P, Wills S, van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006;80(1):1-15
  • Cohly HH, Panja A. Immunological findings in autism. Int Rev Neurobiol 2005;71:317-41
  • Gregg JP, Lit L, Baron CA, et al. Gene expression changes in children with autism. Genomics 2008;91(1):22-9
  • Enstrom AM, Lit L, Onore CE, et al. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun 2009;23:124-33
  • Chez MG, Dowling T, Patel PB, et al. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 2007;36(6):361-5
  • Zimmerman AW, Jyonouchi H, Comi AM, et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 2005;33(3):195-201
  • Li X, Chauhan A, Sheikh AM, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009;207(1-2):111-6
  • Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58(5):445-52
  • Weizman A, Weizman R, Szekely GA, et al. Abnormal immune response to brain tissue antigen in the syndrome of autism. Am J Psychiatry 1982;139(11):1462-5
  • Ashwood P, Schauer J, Pessah IN, de Water JV. Preliminary evidence of the in vitro effects of BDE-47 on innate immune responses in children with autism spectrum disorders. J Neuroimmunol 2009;208:130-5
  • Grigorenko EL, Han SS, Yrigollen CM, et al. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics 2008;122(2):e438-45
  • Vargas DL, Nascimbene C, Krishnan C, et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005;57(1):67-81
  • Conti P, Pang X, Boucher W, et al. Impact of Rantes and MCP-1 chemokines on in vivo basophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997;89:4120-7
  • Ashwood P, Enstrom A, Krakowiak P, et al. Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 2008;204:149-53
  • Gebhardt T, Lorentz A, Detmer F, et al. Growth, phenotype, and function of human intestinal mast cells are tightly regulated by transforming growth factor beta1. Gut 2005;54(7):928-34
  • Gomez G, Ramirez CD, Rivera J, et al. TGF-beta1 inhibits mast cell FcåRI expression. J Immunol 2005;174:5987-93
  • Dahlgren J, Samuelsson AM, Jansson T, Holmang A. Interleukin-6 in the maternal circulation reaches the rat fetus in mid-gestation. Pediatr Res 2006;60(2):147-51
  • Smith SE, Li J, Garbett K, et al. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007;27(40):10695-702
  • Huang M, Pang X, Karalis K, Theoharides TC. Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. Cardiovasc Res 2003;59(1):241-9
  • de Boer AG, Breimer DD. Cytokines and blood-brain barrier permeability. Prog Brain Res 1998;115:425-51
  • Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000;20:131-47
  • Vojdani A, Campbell AW, Anyanwu E, et al. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol 2002;129(1-2):168-77
  • Wills S, Cabanlit M, Bennett J, et al. Detection of autoantibodies to neural cells of the cerebellum in the plasma of subjects with autism spectrum disorders. Brain Behav Immun 2008;23:64-74
  • Singer HS, Morris CM, Williams PN, et al. Antibrain antibodies in children with autism and their unaffected siblings. J Neuroimmunol 2006;178(1-2):149-55
  • Cabanlit M, Wills S, Goines P, et al. Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann NY Acad Sci 2007;1107:92-103
  • Singer HS, Morris CM, Gause CD, et al. Antibodies against fetal brain in sera of mothers with autistic children. J Neuroimmunol 2008;194(1-2):165-72
  • Zimmerman AW, Connors SL, Matteson KJ, et al. Maternal antibrain antibodies in autism. Brain Behav Immun 2007;21(3):351-7
  • Braunschweig D, Ashwood P, Krakowiak P, et al. Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology 2008;29(2):226-31
  • Persico AM, Sacco R, Curatolo P, et al. Isolation of principal components in autistic disorder symptomatology and their association with biological endophenotypes. Proc Society for Neuroscience, Washington; 2008
  • Jyonouchi H, Geng L, Cushing-Ruby A, Quraishi H. Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study. J Neuroinflamm 2008;5:52
  • Lucarelli S, Frediani T, Zingoni AM, et al. Food allergy and infantile autism. Panminerva Med 1995;37(3):137-41
  • Venter C, Pereira B, Voigt K, et al. Prevalence and cumulative incidence of food hypersensitivity in the first 3 years of life. Allergy 2008;63:354-9
  • Teufel M, Biedermann T, Rapps N, et al. Psychological burden of food allergy. World J Gastroenterol 2007;13(25):3456-65
  • Lack G. Food allergy. N Engl J Med 2008;359(12):1252-60
  • Ortolani C, Pastorello EA. Food allergies and food intolerances. Best Pract Res Clin Gastroenterol 2006;20(3):467-83
  • Farhadi A, Fields JZ, Keshavarzian A. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World J Gastroenterol 2007;13(22):3027-30
  • Rijnierse A, Nijkamp FP, Kraneveld AD. Mast cells and nerves tickle in the tummy. Implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther 2007;116:207-35
  • O'Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000;12:449-57
  • Levy SE, Souders MC, Ittenbach RF, et al. Relationship of dietary intake to gastrointestinal symptoms in children with autistic spectrum disorders. Biol Psychiatry 2007;61(4):492-7
  • Valicenti-McDermott MD, McVicar K, Cohen HJ, et al. Gastrointestinal symptoms in children with an autism spectrum disorder and language regression. Pediatr Neurol 2008;39(6):392-8
  • Nikolov RN, Bearss KE, Lettinga J, et al. Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. J Autism Dev Disord 2009;39(3):405-13
  • Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology 2005;51(2):77-85
  • Black C, Kaye JA, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. BMJ 2002;325(7361):419-21
  • Wakefield AJ, Ashwood P, Limb K, Anthony A. The significance of ileo-colonic lymphoid nodular hyperplasia in children with autistic spectrum disorder. Eur J Gastroenterol Hepatol 2005;17(8):827-36
  • Krigsman A, Boris M, Goldblatt A, Scott C. Review of clinical presentation and histologic findings at ileocolonoscopy in children with autistic spectrum disorder and chronic gastrointestinal symtoms. Autism Res 2008. [Epub ahead of print]
  • Liu Z, Li N, Neu J. Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr 2005;94(4):386-93
  • Bode L, Salvestrini C, Park PW, et al. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest 2008;118(1):229-38
  • Lencer WI. Patching a leaky intestine. N Engl J Med 2008;359(5):526-8
  • Alberti A, Pirrone P, Elia M, et al. Sulphation deficit in ‘low-functioning’ autistic children: a pilot study. Biol Psychiatry 1999;46(3):420-4
  • Menage P, Thibault G, Martineau J, et al. An IgE mechanism in autistic hypersensitivity? Biol Psychiatry 1992;31(2):210-2
  • Bakkaloglu B, Anlar B, Anlar FY, et al. Atopic features in early childhood autism. Eur J Paediatr Neurol 2008;12:476-9
  • Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 2002;127:147-52
  • Metcalfe DD, Akin C. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001;25:577-82
  • Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-25
  • Available from: www.tmsforacure.org
  • Theoharides TC, Doyle R, Francis K, et al. Novel therapeutic targets for autism. Trends Pharmacol Sci 2008;29(8):375-82
  • Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002;128:344-50
  • Croen LA, Grether JK, Yoshida CK, et al. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med 2005;159(2):151-7
  • Comi AM, Zimmerman AW, Frye VH, et al. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol 1999;14(6):388-94
  • Theoharides TC, Kalogeromitros D. The critical role of mast cell in allergy and inflammation. Ann NY Acad Sci 2006;1088:78-99
  • Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as ‘tunable’ effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005;23:749-86
  • Bachelet I, Levi-Schaffer F. Mast cells as effector cells: a co-stimulating question. Trends Immunol 2007;28(8):360-5
  • Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004;146:1-12
  • Dimitriadou V, Rouleau A, Trung Tuong MD, et al. Functional relationships between sensory nerve fibers and mast cells of dura mater in normal and inflammatory conditions. Neuroscience 1997;77:829-39
  • Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, et al. Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo. Brain Res 1999;849:1-15
  • Stead RH, Dixon MF, Bramwell NH, et al. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology 1989;97:575-85
  • Blank U, Rivera J. The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol 2004;25:266-73
  • Redegeld FA, Nijkamp FP. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? Trends Immunol 2005;24:181-5
  • Kempuraj D, Tagen M, Iliopoulou BP, et al. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br J Pharmacol 2008;155:1076-84
  • Carraway R, Cochrane DE, Lansman JB, et al. Neurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levels. J Physiol 1982;323:403-14
  • Janiszewski J, Bienenstock J, Blennerhassett MG. Picomolar doses of substance P trigger electrical responses in mast cells without degranulation. Am J Physiol 1994;267:C138-45
  • Kulka M, Sheen CH, Tancowny BP, et al. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008;123(3):398-410
  • Frossi B, de Carli M, Daniel KC, et al. Oxidative stress stimulates IL-4 and IL-6 production in mast cells by an APE/Ref-1-dependent pathway. Eur J Immunol 2003;33:2168-77
  • Kempuraj D, Hogan J, Zhang B, et al. Mercury chloride triggers human mast cells to release vascular endothelial growth factor (VEGF)-relevance to autism. 96th Annual Meeting, The Americal Association of Immunologisits, May 8-12. Immunology; 2009
  • Elferink JG. Thimerosal: a versatile sulfhydryl reagent, calcium mobilizer, and cell function-modulating agent. Gen Pharmacol 1999;33(1):1-6
  • Strenzke N, Grabbe J, Plath KE, et al. Mercuric chloride enhances immunoglobulin E-dependent mediator release from human basophils. Toxicol Appl Pharmacol 2001;174(3):257-63
  • Salamon P, Shoham NG, Gavrieli R, et al. Human mast cells release interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy 2005;60(10):1316-9
  • Nakae S, Suto H, Iikura M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 2006;176(4):2238-48
  • Theoharides TC, Kempuraj D, Tagen M, et al. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007;217:65-78
  • Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. Differential release of serotonin and histamine from mast cells. Nature 1982;297:229-31
  • Okayama Y. Mast cell-derived cytokine expression induced via Fc receptors and Toll-like receptors. Chem Immunol Allergy 2005;87:101-10
  • Varadaradjalou S, Feger F, Thieblemont N, et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 2003;33:899-906
  • McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol 2003;170:1625-9
  • Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol 2004;114(1):174-82
  • Ikeda RK, Miller M, Nayar J, et al. Accumulation of peribronchial mast cells in a mouse model of ovalbumin allergen induced chronic airway inflammation: modulation by immunostimulatory DNA sequences. J Immunol 2003;171(9):4860-7
  • Arvola T, Ruuska T, Keranen J, et al. Rectal bleeding in infancy: clinical, allergological, and microbiological examination. Pediatrics 2006;117(4):e760-8
  • Dunn SJ, Greenberg HB, Ward RL, et al. Serotypic and genotypic characterization of human serotype 10 rotaviruses from asymptomatic neonates. J Clin Microbiol 1993;31(1):165-9
  • Difazio MP, Braun L, Freedman S, Hickey P. Rotavirus-induced seizures in childhood. J Child Neurol 2007;22(12):1367-70
  • Oslejskova H, Dusek L, Makovska Z, et al. Complicated relationship between autism with regression and epilepsy. Neuro Endocrinol Lett 2008;29(4):558-70
  • Pehlivanidis C, Fotoulaki M, Boucher W, et al. Acute stress-induced seizures and loss of consciousness in a ten-year-old boy with cutaneous mastocytosis. J Clin Psychopharmacol 2002;22:221-4
  • Kandere-Grzybowska K, Letourneau R, Kempuraj D, et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol 2003;171(9):4830-6
  • Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005;174:7665-75
  • Theoharides TC, Weinkauf C, Conti P. Brain cytokines and neuropsychiatric disorders. J Clin Psychopharmacol 2004;24:577-81
  • Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci 2007;12:1615-28
  • White SW, Oswald D, Ollendick T, Scahill L. Anxiety in children and adolescents with autism spectrum disorders. Clin Psychol Rev 2009;29:216-29
  • Gillott A, Standen PJ. Levels of anxiety and sources of stress in adults with autism. J Intellect Disabil 2007;11(4):359-70
  • Jansen LM, Gispen-de Wied CC, van der Gaag RJ, van EH. Differentiation between autism and multiple complex developmental disorder in response to psychosocial stress. Neuropsychopharmacology 2003;28(3):582-90
  • Tani P, Lindberg N, Matto V, et al. Higher plasma ACTH levels in adults with Asperger syndrome. J Psychosom Res 2005;58(6):533-6
  • Geier DA, Geier MR. A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders. Horm Res 2006;66(4):182-8
  • Geier DA, Geier MR. A prospective assessment of androgen levels in patients with autistic spectrum disorders: biochemical underpinnings and suggested therapies. Neuro Endocrinol Lett 2007;28(5):565-73
  • Theoharides TC, Spanos CP, Pang X, et al. Stress-induced intracranial mast cell degranulation. A corticotropin releasing hormone-mediated effect. Endocrinology 1995;136:5745-50
  • Esposito P, Chandler N, Kandere-Grzybowska K, et al. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 2002;303:1061-6
  • Esposito P, Gheorghe D, Kandere K, et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 2001;888:117-27
  • Theoharides TC. Mast cells: the immune gate to the brain. Life Sci 1990;46:607-17
  • Silver R, Silverman A-J, Vitkovic L, Lederhendler II. Mast cells in the brain: evidence and functional significance. Trends Neurosci 1996;19:25-31
  • Theoharides TC, Singh LK, Boucher W, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. Endocrinology 1998;139:403-13
  • Crompton R, Clifton VL, Bisits AT, et al. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. J Clin Endocrinol Metab 2003;88:5427-32
  • Akin C, Valent P, Escribano L. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr Allergy Asthma Rep 2006;6(4):282-8
  • Theoharides TC, Kempuraj D, Marchand J, et al. Urticaria pigmentosa associated with acute stress and lesional skin mast cell expression of CRF-R1. Clin Exp Dermatol 2009;34:e163-6
  • Theoharides TC, Letourneau R, Patra P, et al. Stress-induced rat intestinal mast cell intragranular activation and inhibitory effect of sulfated proteoglycans. Dig Dis Sci 1999;44:87S-93S
  • Castagliuolo I, Lamont JT, Qiu B, et al. Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am J Physiol 1996;271:884-92
  • Kokkotou E, Torres D, Moss AC, et al. Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol 2006;177(5):3355-61
  • La Fleur SE, Wick EC, Idumalla PS, et al. Role of peripheral corticotropin-releasing factor and urocortin II in intestinal inflammation and motility in terminal ileum. Proc Natl Acad Sci USA 2005;102(21):7647-52
  • Wallon C, Yang P, Keita AV, et al. Corticotropin releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008;57:50-8
  • Umathe SN, Bhutada PS, Jain NS, et al. Gonadotropin-releasing hormone agonist blocks anxiogenic-like and depressant-like effect of corticotrophin-releasing hormone in mice. Neuropeptides 2008;42(4):399-410
  • Umathe SN, Dixit PV, Wanjari MM, Ullewar MP. Leuprolide–a GnRH agonist–prevents restraint stress-induced immunosuppression via sex steroid-independent peripheral mechanism in mice. Int Immunopharmacol 2008;8(1):71-9
  • Barreau F, Cartier C, Leveque M, et al. Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay. J Physiol 2007;580(Pt 1):347-56
  • Barreau F, Salvador-Cartier C, Houdeau E, et al. Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats. Gut 2008;57(5):582-90
  • Wright RJ, Finn P, Contreras JP, et al. Chronic caregiver stress and IgE expression, allergen-induced proliferation, and cytokine profiles in a birth cohort predisposed to atopy. J Allergy Clin Immunol 2004;113(6):1051-7
  • Theoharides TC, Doyle R. Autism, gut-blood-brain barrier and mast cells. J Clin Psychopharmacol 2008;28(5):479-83
  • Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother 2007;8(11):1579-603
  • Broadstock M, Doughty C, Eggleston M. Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorder. Autism 2007;11(4):335-48
  • Rogers SJ, Vismara LA. Evidence-based comprehensive treatments for early autism. J Clin Child Adolesc Psychol 2008;37(1):8-38
  • Findling RL. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. J Clin Psychiatry 2005;66(Suppl 10):26-31
  • Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 2008;16(2):97-112
  • West L, Waldrop J, Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009;23(2):75-89
  • Liptak GS, Stuart T, Auinger P. Health care utilization and expenditures for children with autism: data from U.S. national samples. J Autism Dev Disord 2006;36(7):871-9
  • Oswald DP, Sonenklar NA. Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol 2007;17(3):348-55
  • Gerhard T, Chavez B, Olfson M, Crystal S. National patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorder. J Clin Psychopharmacol 2009
  • Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005;30(3):582-9
  • Tandon M, Pruett JR Jr. An overview of the use of antidepressants in children and adolescents. Mo Med 2008;105(1):79-84
  • Posey DJ, Stigler KA, Erickson CA, McDougle CJ. Antipsychotics in the treatment of autism. J Clin Invest 2008;118(1):6-14
  • Morgan S, Taylor E. Antipsychotic drugs in children with autism. BMJ 2007;334(7603):1069-70
  • Chavez B, Chavez-Brown M, Sopko MA, et al. Atypical antipsychotics in children with pervasive developmental disorders. Paediatr Drugs 2007;9(4):249-66
  • McDougle CJ, Stigler KA, Erickson CA, Posey DJ. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008;69(Suppl 4):15-20
  • Mandell DS, Morales KH, Marcus SC, et al. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 2008;121(3):e441-8
  • Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 2008;18(2):157-78
  • Research units on pediatric psychparmacology autism network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62(11):1266-74
  • McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347(5):314-21
  • Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs 2007;9(5):343-54
  • Peachell PT, Pearce FL. Divalent cation dependence of the inhibition by phenothiazines of mediator release from mast cells. Br J Pharmacol 1989;97(2):547-55
  • Akhondzadeh S, Erfani S, Mohammadi MR, et al. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. J Clin Pharm Ther 2004;29(2):145-50
  • Hranilovic D, Bujas-Petkovic Z, Vragovic R, et al. Hyperserotonemia in adults with autistic disorder. J Autism Dev Disord 2007;37(10):1934-40
  • de Giorgio R, Barbara G, Furness JB, Tonini M. Novel therapeutic targets for enteric nervous system disorders. Trends Pharmacol Sci 2007;28(9):473-81
  • Curtis LT, Patel K. Nutritional and environmental approaches to preventing and treating autism and attention deficit hyperactivity disorder (ADHD): a review. J Altern Complement Med 2008;14(1):79-85
  • Adams JB. Summary of biomedical treatments for autism. Autism Research Institute (ARI) Publication 2008;40:1-27
  • Weber W, Newmark S. Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. Pediatr Clin North Am 2007;4(6):983-1006
  • James SJ, Melnyk S, Fuchs G, et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr 2009;89(1):425-30
  • Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000;52:673-751
  • Beretz A, Cazenave JP, Anton R. Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: structure-activity relationships. Agents Actions 1982;12:382-7
  • Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA 2008;105(21):7534-9
  • Sharma V, Mishra M, Ghosh S, et al. Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection. Brain Res Bull 2007;73(1-3):55-63
  • Kumar A, Goyal R. Quercetin protects against acute immobilization stress-induced behaviors and biochemical alterations in mice. J Med Food 2008;11(3):469-73
  • Kimata M, Shichijo M, Miura T, et al. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 2000;30:501-8
  • Kempuraj D, Madhappan B, Christodoulou S, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 2005;145:934-44
  • Kandere-Grzybowska K, Kempuraj D, Cao J, et al. Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin.Br J Pharmacol 2006;148:208-15
  • Harwood M, Nielewska-Nikiel B, Borzelleca JF, et al. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007;45(11):2179-205
  • Manach C, Donovan JL. Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radic Res 2004;38(8):771-85
  • Erlund I, Kosonen T, Alfthan G, et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 2000;56(8):545-53
  • Theoharides TC, Patra P, Boucher W, et al. Chondroitin sulfate inhibits connective tissue mast cells. Br J Pharmacol 2000;131:1039-49
  • Vasiadi M, Kalogeromitros K, Kempuraj D, et al. Rupatadine inhibits pro-inflammatory mediator secretion from human mast cells. Clin Exp Allergy 2009. In press
  • Elchaar GM, Maisch NM, Augusto LM, Wehring HJ. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother 2006;40(6):1086-95
  • Barke KE, Hough LB. Opiates, mast cells and histamine release. Life Sci 1993;53:1391-9
  • Bertoglio K, Hendren RL. New developments in autism. Psychiatr Clin North Am 2009;32(1):1-14
  • Theoharides TC, Wang L, Pang X, et al. Cloning and cellular localization of the rat mast cell 78kD protein phosphorylated in response to the mast cell ‘stabilizer’ cromolyn. J Pharmacol Exp Ther 2000;294:810-21
  • Tagen M, Elorza A, Boucher W, et al. The mitochondrial uncoupling protein 2 (UCP2) inhibits mast cell activation and reduces histamine content. J Immunol 2009. In press
  • Kamide R, Niimura M, Ueda H, et al. Clinical evaluation of ketotifen for chronic urticaria: multicenter double-blind comparative study with clemastine.Ann Allergy 1989;62:322-5
  • Weissman JR, Kelley RI, Bauman ML, et al. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PLoS One 2008;3(11):e3815
  • King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009;66(6):583-90
  • Volkmar FR. Citalopram treatment in children with autism spectrum disorders and high levels of repetitive behavior. Arch Gen Psychiatry 2009;66(6):581-2

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.